)
)
)
Bankers, Investors, and Biotech: What Would IPO Success in 2026 Require?
The pace of US biotech IPOs stalled for much of 2025 but reductions in interest rates corelate with an uptick in new offerings as investors reconsider the risks and returns from new medicines in this dynamic commercial landscape. This session will examine which technologies, therapeutic areas, and types of messages are most resonating with IPO investors.
Speakers
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
